tirzepatide kidney damage Interplay of Chronic Disease and the Effects of in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial Mounjaro seems good for kidney

Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks

Deficiency is more common than most people assume: estimated at 12% of the US general population and considerably higher in athletes due to sweat losses

Strong reputation among integrative and functional-medicine practitioners for consistent quality and reliable potency

Little to no weight effect expected

Diurnal changes in melatonin binding sites of hamster and rat brains